LUNDBECK Pricing & Demo

Are you from this Company?
LUNDBECK
Write a Review
Copenhagen, Denmark
1915
$1BN to $5BN
Enterprise
82 Likes
75 Buyers Negotiating
Summary
No Summary And Details

Popular Comparisons

Discussions

Strengths
  • +11
    Product Branding
  • +10
    Unique and Compelling Differentiating Factor
  • +6
    Anticholinergic
  • +13
    Capsule
  • +7
    Other
  • +12
    Tablet
  • +8
    Branded Drug
  • +9
    Generic Drug
  • +11
    Others
  • +9
    Product Differentiation and Impact on Customer Value
  • +7
    R&D Expenditure
  • +6
    Product Features and Functionality
  • +8
    Focus on Product Innovation
  • +5
    COMT-Inhibitor
  • +13
    Dopamine Receptor Agonist
  • +12
    Levodopa cardbidopa therapy
  • +14
    MAO-Inhibitor
  • +5
    Patch
  • +14
    Solution
  • +10
    Anticholinergics
Cautions
  • -9
    COMT-Inhibitors
  • -7
    Dopamine Receptor Agonists
  • -6
    Levodopa/cardbidopa therapy
  • -8
    MAO-Inhibitors
  • -7
    Breadth and Depth of Product Offerings
LUNDBECK Presence in Parkinson's Disease Treatment
H.Lundbeck adopts inorganic growth strategies to sustain its leadership in the Parkinson’s disease treatment market. In 2014, the company acquired Chelsea Therapeutics to strengthen its position in the US. With this acquisition, the company added NORTHERA to its product portfolio.
I agree to 360Quadrants Terms of use and privacy policy
Success
info
Error
Company Size :
  Enterprise
  SME
  Startup
logo-360
  • saved

    You haven’t saved anything yet

    To save, search for Vendors by
    Name or Category, then tap the heart